Last reviewed · How we verify

NCT03786016

Evaluating Risk Factors and Biomarkers for Adaptation and Resilience to Spaceflight

Completed NA Last updated 6 April 2025
What this trial tests

NA trial testing 8-Days in an Isolation, Confinement Unit in Resilience in 32 participants. Completed in 28 February 2025.

Timeline
22 February 2019
Primary endpoint
10 December 2024
28 February 2025

Quick facts

Lead sponsorUniversity of Pennsylvania
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment32
Start date22 February 2019
Primary completion10 December 2024
Estimated completion28 February 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Pennsylvania

Who can join

Adults 30 to 55, any sex, with Resilience or Mood. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study assesses differences in biological and behavioral domains that relate to individual adaptation and resiliency to an isolated, confined and controlled environment, and evaluates the effect of confinement, work, monotony, and social and physical isolation on stress resiliency and well-being.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Resilience

Currently open trials in the same condition.

Other University of Pennsylvania trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03786016.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing